Pieris Pharmaceuticals, Inc.: Platform technology company developing Anticalin proteins (engineered human lipocalins) for respiratory diseases and oncology. Upcoming Phase 1 data for data for: 1) AZN-partnered PRS-060 for moderate-to-severe asthma (targeting IL4RA through inhalation) and 2) fully-proprietary IO program PRS-343 for HER2+ solid tumors (targeting 4-1BB and HER2). IO partnerships w/ Servier and Seattle Genetics.
Sector/industry:
Healthcare/Biotechnology
Characteristics:
Based in...
USA
Clinical Stage
Phase l or ll
Disease Space
Immuno-Oncology, Immunotherapy, Oncology, Respiratory
Finance
Pre-earnings
Industry
Biotechnology
Listing
Public, USA
Market Cap
100MM - 500MM
Therapeutic Modalities
Antibodies, Platform Technology
Website:
Profiles:
Address:
255 State Street
Boston, MA 02109
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Upcoming Company Event Participation

Pieris Pharmaceuticals R&D Day

New York, November 19, 2019

Solebury Trout Management Access: SF 2020

San Francisco, CA, United States, January 13 – January 16, 2020

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.